Literature DB >> 20008287

Nucleotide oligomerization binding domain-like receptor signaling enhances dendritic cell-mediated cross-priming in vivo.

Jumpei Asano1, Hiroyuki Tada, Nobuyuki Onai, Taku Sato, Yasuo Horie, Yukari Fujimoto, Koichi Fukase, Akira Suzuki, Tak W Mak, Toshiaki Ohteki.   

Abstract

Nucleotide oligomerization binding domain (Nod)-like receptors are critical cytosolic sensors for the recognition of bacterial peptidoglycan. However, their role in the induction of dendritic cell (DC)-mediated cross-priming remains unclear. In this study, we demonstrate that injecting ligands for Nod1 and Nod2 along with Ag into wild-type mice significantly enhanced the cross-priming of Ag-specific CD8+ T cells by CD8alpha+ DCs, as assessed from the expansion of IFN-gamma+ CD8+ T cells, CTL activity against Ag-pulsed targets, and the rejection of transplanted tumors expressing the cognate Ag. The enhancement of CD8alpha+ DC-mediated cross-priming was likely due to the upregulation of Ag cross-presentation and of costimulatory molecules. Our findings collectively indicate that Nod1/2 signaling is critical for the optimal induction of DC cross-priming in vivo, which may offer an alternative therapeutic pathway in cancer and hosts refractory to TLR signals or paralyzed by viral evasion strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008287     DOI: 10.4049/jimmunol.0900726

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

2.  TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation.

Authors:  Claudia S Wagner; Peter Cresswell
Journal:  J Immunol       Date:  2011-12-09       Impact factor: 5.422

3.  The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation.

Authors:  Michael H Shaw; Nobuhiko Kamada; Neil Warner; Yun-Gi Kim; Gabriel Nuñez
Journal:  Trends Immunol       Date:  2011-01-19       Impact factor: 16.687

4.  Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy.

Authors:  Matthew E Griffin; Juliel Espinosa; Jessica L Becker; Ji-Dung Luo; Thomas S Carroll; Jyoti K Jha; Gary R Fanger; Howard C Hang
Journal:  Science       Date:  2021-08-27       Impact factor: 63.714

Review 5.  Presentation of phagocytosed antigens by MHC class I and II.

Authors:  Adriana R Mantegazza; Joao G Magalhaes; Sebastian Amigorena; Michael S Marks
Journal:  Traffic       Date:  2012-11-29       Impact factor: 6.215

Review 6.  Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure.

Authors:  Sheryl Coutermarsh-Ott; Kristin Eden; Irving Coy Allen
Journal:  J Gen Virol       Date:  2016-01-13       Impact factor: 3.891

Review 7.  NOD1 and NOD2 in inflammatory and infectious diseases.

Authors:  Bruno C Trindade; Grace Y Chen
Journal:  Immunol Rev       Date:  2020-07-17       Impact factor: 12.988

8.  Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells.

Authors:  Masahiro Azuma; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

Review 9.  Beyond pattern recognition: NOD-like receptors in dendritic cells.

Authors:  Jayendra Kumar Krishnaswamy; Thach Chu; Stephanie C Eisenbarth
Journal:  Trends Immunol       Date:  2013-01-23       Impact factor: 16.687

10.  NOD1 cooperates with TLR2 to enhance T cell receptor-mediated activation in CD8 T cells.

Authors:  Blandine C Mercier; Erwan Ventre; Marie-Laure Fogeron; Anne-Laure Debaud; Martine Tomkowiak; Jacqueline Marvel; Nathalie Bonnefoy
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.